July 2026
1. SCARIA PV, Chen B, Muratova O, Kemanli P, et al
   Impact of antigen and carrier substitution on the molecular weight and immunogenicity of the Pfs230D1-CRM197 malaria transmission-blocking vaccine.
   Vaccine. 2026;88:128913.
   

   >> Share

   
   June 2026
2. WHITWORTH HS, Beshir KB, Baisley KJ, Mbwanji G, et al
   Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.
   Vaccine. 2026;89:128889.
   

   >> Share

   
   
3. NTUMNGIA FB, Kolli SK, Howard GP, Subramani PA, et al
   Evaluation of immunogenicity and efficacy of a Plasmodium vivax nanoparticle vaccine in mice.
   Vaccine. 2026;88:128857.
   

   >> Share

   
   
4. SAFARI MS, Gicheru ET, Mburu MW, Makori TO, et al
   Longitudinal evidence of differential pertussis antibody durability following natural infection among vaccinated children living in contrasting malaria transmission settings in coastal Kenya.
   Vaccine. 2026;88:128837.
   

   >> Share

   
   
5. POURHASHEM Z, Siasi S, Nourani L, Yousefi H, et al
   Corrigendum to "Multi-antigen transmission-blocking malaria vaccine elicits Th1-biased antibody responses and SMFA-confirmed oocyst reduction in Anopheles stephensi" [Vaccine 84 (2026) 128683].
   Vaccine. 2026;88:128784.
   

   >> Share

   
   May 2026
6. POURHASHEM Z, Siasi S, Nourani L, Yousefi H, et al
   Multi-antigen transmission-blocking malaria vaccine elicits Th1-biased antibody responses and SMFA-confirmed oocyst reduction in Anopheles stephensi.
   Vaccine. 2026;84:128683.
   

   >> Share

   
   April 2026
7. GOTHAM D, Frick M, Harrington M
   Understanding adjuvant supply chains for new TB and malaria vaccines.
   Vaccine. 2026;82:128609.
   

   >> Share

   
   
8. LAURENSON AJ, Pierce BG, Takala-Harrison S, Laurens MB, et al
   TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes.
   Vaccine. 2026;77:128388.
   

   >> Share

   
   March 2026
9. D'ALESSIO F, Honkpehedji J, Sirima S, Gamain B, et al
   Immunization strategies to prevent malaria in pregnancy - a multistakeholder workshop.
   Vaccine. 2026;79:128505.
   

   >> Share

   
   February 2026
10. KRETCHY IA, Bonful HA, Opoku-Mireku M, Koduah A, et al
    Impact of caregivers' perceptions of malaria on their hesitancy toward childhood malaria vaccination.
    Vaccine. 2026;77:128389.
    

    >> Share

    
    
11. AL-ABBOODI A, Falih IQ, Al-Asadi M, Hussein BA, et al
    Iron-oxide nanoparticles (SPIONs) enhance malaria vaccine antibody response.
    Vaccine. 2026;77:128353.
    

    >> Share

    
    January 2026
12. HONG H, Eom TH, Lee E, Lee E, et al
    Immunological response of using emulsifying elongation factor 1 alpha of Plasmodium falciparum-based vaccines in complete Freund's adjuvant.
    Vaccine. 2026;75:128279.
    

    >> Share

    
    December 2025
13. PINANDYO SH, Ali S, Aurelio B, Amoah AS, et al
    The association of helminth infection against antimalarial antibody responses in malaria infection and vaccination: a systematic review and meta-analysis.
    Vaccine. 2025;73:128125.
    

    >> Share

    
    November 2025
14. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
    Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].
    Vaccine. 2025;69:127973.
    

    >> Share

    
    
15. BIRKETT AJ, Ansah E, Gordon S, Gyapong M, et al
    Value profile for Malaria vaccines and monoclonal antibodies.
    Vaccine. 2025 Nov 15:127971. doi: 10.1016/j.vaccine.2025.127971.
    

    >> Share

    
    
16. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
    Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM.
    Vaccine. 2025;68:127897.
    

    >> Share

    
    October 2025
17. ANOSIKE C, Ojiakor IM, Etiaba EI, Uguru NP, et al
    Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review.
    Vaccine. 2025;67:127853.
    

    >> Share

    
    
18. BELMONTE M, Kusi KA, Kyei-Baafour E, Ofori EA, et al
    Immunogenicity of HLA-restricted peptide vaccine candidates delivered by self-assembling protein nanoparticle (SAPN) technology.
    Vaccine. 2025;66:127832.
    

    >> Share

    
    September 2025
19. ZHAO Z, Ma X, Milligan P, Cheung YB, et al
    Robust evaluation of vaccine effects based on estimation of vaccine efficacy curve.
    Vaccine. 2025;63:127673.
    

    >> Share

    
    July 2025
20. NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al
    Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey.
    Vaccine. 2025;60:127323.
    

    >> Share

    
    June 2025
21. HASSAN IA, Araoye JB, Olawuyi DA, Effiong FB, et al
    Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
    Vaccine. 2025;61:127376.
    

    >> Share

    
    May 2025
22. YUN SY, Nguyen MN, Hong H, Bae GJ, et al
    Immunogenicity and efficacy in mice of two adjuvant formulations based on the C -and N-terminus of merozoite surface protein 1 of Plasmodium yoelii.
    Vaccine. 2025;55:127032.
    

    >> Share

    
    April 2025
23. PARVEEN S, Rath PP, Tabrez S, Khan S, et al
    Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy.
    Vaccine. 2025;54:126993.
    

    >> Share

    
    
24. FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al
    Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged with vector-borne pathogens.
    Vaccine. 2025;53:127076.
    

    >> Share

    
    
25. DESHMUKH B, Khatri D, Kochar SK, Athale C, et al
    In vitro evaluation of multi-protein chimeric antigens in effectively clearing the blood stage of Plasmodium falciparum.
    Vaccine. 2025;53:126952.
    

    >> Share

    
    
26. MO AX, McGugan G, Pesce JT
    Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
    Vaccine. 2025;54:127009.
    

    >> Share

    
    February 2025
27. SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al
    Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy.
    Vaccine. 2025;50:126783.
    

    >> Share

    
    January 2025
28. CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al
    Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
    Vaccine. 2025;47:126696.
    

    >> Share

    
    October 2024
29. ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al
    RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.
    Vaccine. 2024;42:126490.
    

    >> Share

    
    July 2024
30. SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al
    The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.
    Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173.
    

    >> Share

    
    
31. CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
    Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    May 2024
32. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
33. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    April 2024
34. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    March 2024
35. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    February 2024
36. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    
37. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    

    >> Share

    
    November 2023
38. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    
39. HAYASHI CTH, Cao Y, Zavala F, Simonyan H, et al
    Antibodies elicited by Plasmodium falciparum circumsporozoite proteins lacking sequentially deleted C-terminal amino acids reveal mouse strain and epitopes specific differences.
    Vaccine. 2023;41:6824-6833.
    

    >> Share

    
    August 2023
40. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    May 2023
41. SIMONS LM, Ferrer P, Gombakomba N, Underwood K, et al
    Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Vaccine. 2023;41:3367-3379.
    

    >> Share

    
    April 2023
42. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share